Scroll Back to Top
Accessibility
Accessibility

PD-L1 Quantitative by IHC

CPT 88360
Synonyms
  • PD-L1 Non-specific

Test Details

View Requisition Forms

Use

PD-L1 overexpression is associated with adverse prognosis in solid tumors, though specific prognosis varies among different tumor types. The utility of this PD-L1 (22C3) assay in predicting the response to therapy has not been determined for all tumor types, and standardized scoring methods do not exist for all tumor types.

Special Instructions

Note: This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete, based on the processes performed in the laboratory.

Limitations

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Methodology

Immunohistochemistry

References

Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore). 2017 May;96(18):e6369.28471952
Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One. 2015 Jun 26;10(6):e013140.26114883

Specimen Requirements

Information on collection, storage, and volume

Specimen

Formalin-fixed paraffin-embedded (FFPE) tissue block or slides

Volume

One tissue block or five unstained positively charged slides less than one month in age

Minimum Volume

At least three unstained slides sectioned at 4-5 microns

Container

Paraffin block or unstained positive charged slides

Causes for Rejection

Slides sectioned greater than one month prior to test request

Collection

Paraffin block or unstained slides sectioned of no more than one month age.

Request Supplies